{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:11:06Z","timestamp":1792440666288,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00228-025-03980-x","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:05:12Z","timestamp":1768802712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systematic analysis of the adverse effects of used clinical antisense oligonucleotide drugs in DMD patients based on the FAERS database"],"prefix":"10.1007","volume":"82","author":[{"given":"Xiao-fang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Guang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"3980_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","volume":"15","author":"S Crisafulli","year":"2020","unstructured":"Crisafulli S, Sultana J, Fontana A et al (2020) Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet J Rare Dis 15:141. https:\/\/doi.org\/10.1186\/s13023-020-01430-8","journal-title":"Orphanet J Rare Dis"},{"key":"3980_CR2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40272-024-00655-5","volume":"26","author":"C Pascual-Morena","year":"2024","unstructured":"Pascual-Morena C, Lucer\u00f3n-Lucas-Torres M, Mart\u00ednez-Garc\u00eda I et al (2024) Efficacy and safety of Vamorolone in Duchenne muscular dystrophy: A systematic review. Paediatr Drugs 26:695\u2013707. https:\/\/doi.org\/10.1007\/s40272-024-00655-5","journal-title":"Paediatr Drugs"},{"key":"3980_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/S1474-4422(22)00125-9","volume":"21","author":"T Markati","year":"2022","unstructured":"Markati T, Oskoui M, Farrar MA et al (2022) Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol 21:814\u2013829. https:\/\/doi.org\/10.1016\/S1474-4422(22)00125-9","journal-title":"Lancet Neurol"},{"key":"3980_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-025-02758-6","author":"C Pascual-Morena","year":"2025","unstructured":"Pascual-Morena C, Pati\u00f1o-Cardona S, Mart\u00ednez-Garc\u00eda I et al (2025) Efficacy of delandistrogene Moxeparvovec on Duchenne muscular dystrophy: a systematic review and meta-analysis. Hum Genet. https:\/\/doi.org\/10.1007\/s00439-025-02758-6","journal-title":"Hum Genet"},{"key":"3980_CR5","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2018) Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet Lond Engl 391:451\u2013461. https:\/\/doi.org\/10.1016\/S0140-6736(17)32160-8","journal-title":"Lancet Lond Engl"},{"key":"3980_CR6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/humu.23953","volume":"41","author":"C Ling","year":"2020","unstructured":"Ling C, Dai Y, Fang L et al (2020) Exonic rearrangements in DMD in Chinese Han individuals affected with Duchenne and Becker muscular dystrophies. Hum Mutat 41:668\u2013677. https:\/\/doi.org\/10.1002\/humu.23953","journal-title":"Hum Mutat"},{"key":"3980_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S et al (2015) The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36:395\u2013402. https:\/\/doi.org\/10.1002\/humu.22758","journal-title":"Hum Mutat"},{"key":"3980_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00204-021-03184-z","volume":"96","author":"O Sheikh","year":"2022","unstructured":"Sheikh O, Yokota T (2022) Pharmacology and toxicology of Eteplirsen and SRP-5051 for DMD exon 51 skipping: an update. Arch Toxicol 96:1\u20139. https:\/\/doi.org\/10.1007\/s00204-021-03184-z","journal-title":"Arch Toxicol"},{"key":"3980_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.tips.2022.04.009","volume":"43","author":"SE Zakeri","year":"2022","unstructured":"Zakeri SE, Pradeep SP, Kasina V et al (2022) Casimersen for the treatment of Duchenne muscular dystrophy. Trends Pharmacol Sci 43:607\u2013608. https:\/\/doi.org\/10.1016\/j.tips.2022.04.009","journal-title":"Trends Pharmacol Sci"},{"key":"3980_CR10","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Viltolarsen: first approval. Drugs 80:1027\u20131031. https:\/\/doi.org\/10.1007\/s40265-020-01339-3","journal-title":"Drugs"},{"key":"3980_CR11","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C et al (2020) Increased dystrophin production with Golodirsen in patients with Duchenne muscular dystrophy. Neurology 94:e2270\u2013e2282. https:\/\/doi.org\/10.1212\/WNL.0000000000009233","journal-title":"Neurology"},{"key":"3980_CR12","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/dmd.121.000418","volume":"50","author":"F Alhamadani","year":"2022","unstructured":"Alhamadani F, Zhang K, Parikh R et al (2022) Adverse drug reactions and toxicity of the food and drug Administration-Approved antisense oligonucleotide drugs. Drug Metab Dispos Biol Fate Chem 50:879\u2013887. https:\/\/doi.org\/10.1124\/dmd.121.000418","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"3980_CR13","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","volume":"364","author":"NM Goemans","year":"2011","unstructured":"Goemans NM, Tulinius M, van den Akker JT et al (2011) Systemic administration of PRO051 in duchenne\u2019s muscular dystrophy. N Engl J Med 364:1513\u20131522. https:\/\/doi.org\/10.1056\/NEJMoa1011367","journal-title":"N Engl J Med"},{"key":"3980_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/0192623314551840","volume":"43","author":"KS Frazier","year":"2015","unstructured":"Frazier KS (2015) Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist\u2019s perspective. Toxicol Pathol 43:78\u201389. https:\/\/doi.org\/10.1177\/0192623314551840","journal-title":"Toxicol Pathol"},{"key":"3980_CR15","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10:796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"key":"3980_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3980_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10:483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3980_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR et al (1998) A bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466","journal-title":"Eur J Clin Pharmacol"},{"key":"3980_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"W Dumouchel","year":"1999","unstructured":"Dumouchel W (1999) Bayesian data mining in large frequency Tables, with an application to the FDA spontaneous reporting system. Am Stat 53:177\u2013190. https:\/\/doi.org\/10.1080\/00031305.1999.10474456","journal-title":"Am Stat"},{"key":"3980_CR20","doi-asserted-by":"publisher","first-page":"e2353094","DOI":"10.1001\/jamanetworkopen.2023.53094","volume":"7","author":"D Hong","year":"2024","unstructured":"Hong D, Avorn J, Wyss R, Kesselheim AS (2024) Characteristics of patients receiving novel muscular dystrophy drugs in trials vs routine care. JAMA Netw Open 7:e2353094. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.53094","journal-title":"JAMA Netw Open"},{"key":"3980_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.nmd.2023.08.008","volume":"33","author":"C Liu","year":"2023","unstructured":"Liu C, Ma J, Lu Y et al (2023) Clinical, pathological, and genetic characterization in a large Chinese cohort with female dystrophinopathy. Neuromuscul Disord 33:728\u2013736. https:\/\/doi.org\/10.1016\/j.nmd.2023.08.008","journal-title":"Neuromuscul Disord"},{"key":"3980_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.nmd.2017.03.011","volume":"27","author":"E Takeshita","year":"2017","unstructured":"Takeshita E, Minami N, Minami K et al (2017) Duchenne muscular dystrophy in a female with compound heterozygous contiguous exon deletions. Neuromuscul Disord NMD 27:569\u2013573. https:\/\/doi.org\/10.1016\/j.nmd.2017.03.011","journal-title":"Neuromuscul Disord NMD"},{"key":"3980_CR23","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/jmg.2004.021626","volume":"41","author":"V Cantagrel","year":"2004","unstructured":"Cantagrel V, Lossi A-M, Boulanger S et al (2004) Disruption of a new X linked gene highly expressed in brain in a family with two mentally retarded males. J Med Genet 41:736\u2013742. https:\/\/doi.org\/10.1136\/jmg.2004.021626","journal-title":"J Med Genet"},{"key":"3980_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00282093","volume":"74","author":"J Chelly","year":"1986","unstructured":"Chelly J, Marlhens F, Le Marec B et al (1986) De Novo DNA microdeletion in a Girl with Turner syndrome and Duchenne muscular dystrophy. Hum Genet 74:193\u2013196. https:\/\/doi.org\/10.1007\/BF00282093","journal-title":"Hum Genet"},{"key":"3980_CR25","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z et al (2013) Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol 74:637\u2013647. https:\/\/doi.org\/10.1002\/ana.23982","journal-title":"Ann Neurol"},{"key":"3980_CR26","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3389\/fmicb.2018.00750","volume":"9","author":"Y Nan","year":"2018","unstructured":"Nan Y, Zhang Y-J (2018) Antisense phosphorodiamidate morpholino oligomers as novel antiviral compounds. Front Microbiol 9:750. https:\/\/doi.org\/10.3389\/fmicb.2018.00750","journal-title":"Front Microbiol"},{"key":"3980_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13395-015-0070-6","volume":"5","author":"MC Vila","year":"2015","unstructured":"Vila MC, Klimek MB, Novak JS et al (2015) Elusive sources of variability of dystrophin rescue by exon skipping. Skelet Muscle 5:44. https:\/\/doi.org\/10.1186\/s13395-015-0070-6","journal-title":"Skelet Muscle"},{"key":"3980_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Kuntz NL, Koenig E et al (2021) Safety, tolerability, and pharmacokinetics of Casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve 64:285\u2013292. https:\/\/doi.org\/10.1002\/mus.27347","journal-title":"Muscle Nerve"},{"key":"3980_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/nat.2021.0043","volume":"32","author":"L Servais","year":"2022","unstructured":"Servais L, Mercuri E, Straub V et al (2022) Long-Term safety and efficacy data of Golodirsen in ambulatory patients with Duchenne muscular dystrophy amenable to exon 53 skipping: A First-in-human, Multicenter, Two-Part, Open-Label, phase 1\/2 trial. Nucleic Acid Ther 32:29\u201339. https:\/\/doi.org\/10.1089\/nat.2021.0043","journal-title":"Nucleic Acid Ther"},{"key":"3980_CR30","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM et al (2020) Safety, Tolerability, and efficacy of Viltolarsen in boys with Duchenne muscular dystrophy amenable to exon 53 skipping: A phase 2 randomized clinical trial. JAMA Neurol 77:982\u2013991. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1264","journal-title":"JAMA Neurol"},{"key":"3980_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/DDDT.S97635","volume":"11","author":"KRQ Lim","year":"2017","unstructured":"Lim KRQ, Maruyama R, Yokota T (2017) Eteplirsen in the treatment of Duchenne muscular dystrophy. Drug Des Devel Ther 11:533\u2013545. https:\/\/doi.org\/10.2147\/DDDT.S97635","journal-title":"Drug Des Devel Ther"},{"key":"3980_CR32","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.chest.2021.08.078","volume":"161","author":"AM Barnard","year":"2022","unstructured":"Barnard AM, Lott DJ, Batra A et al (2022) Characterizing expiratory respiratory muscle degeneration in Duchenne muscular dystrophy using MRI. Chest 161:753\u2013763. https:\/\/doi.org\/10.1016\/j.chest.2021.08.078","journal-title":"Chest"},{"key":"3980_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1136\/thoraxjnl-2022-218798","volume":"77","author":"DJ Birnkrant","year":"2022","unstructured":"Birnkrant DJ, Carter JC (2022) Back to basics: the respiratory management of Duchenne muscular dystrophy. Thorax 77:743\u2013744. https:\/\/doi.org\/10.1136\/thoraxjnl-2022-218798","journal-title":"Thorax"},{"key":"3980_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-018-0834-2","volume":"13","author":"Y Shimizu-Motohashi","year":"2018","unstructured":"Shimizu-Motohashi Y, Murakami T, Kimura E et al (2018) Exon skipping for Duchenne muscular dystrophy: a systematic review and meta-analysis. Orphanet J Rare Dis 13:93. https:\/\/doi.org\/10.1186\/s13023-018-0834-2","journal-title":"Orphanet J Rare Dis"},{"key":"3980_CR35","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.jvsv.2022.03.007","volume":"10","author":"M Yeow","year":"2022","unstructured":"Yeow M, Soh S, Yap R et al (2022) A systematic review and network meta-analysis of randomized controlled trials on choice of central venous access device for delivery of chemotherapy. J Vasc Surg Venous Lymphat Disord 10:1184\u20131191e8. https:\/\/doi.org\/10.1016\/j.jvsv.2022.03.007","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"3980_CR36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.nmd.2017.05.009","volume":"27","author":"AS Robertson","year":"2017","unstructured":"Robertson AS, Majchrzak MJ, Smith CM et al (2017) Dramatic elevation in urinary amino terminal Titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents. Neuromuscul Disord NMD 27:635\u2013645. https:\/\/doi.org\/10.1016\/j.nmd.2017.05.009","journal-title":"Neuromuscul Disord NMD"},{"key":"3980_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2017.10.082","volume":"49","author":"L Randeree","year":"2018","unstructured":"Randeree L, Eslick GD (2018) Eteplirsen for paediatric patients with Duchenne muscular dystrophy: A pooled-analysis. J Clin Neurosci Off J Neurosurg Soc Australas 49:1\u20136. https:\/\/doi.org\/10.1016\/j.jocn.2017.10.082","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"3980_CR38","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17:347\u2013361. https:\/\/doi.org\/10.1016\/S1474-4422(18)30025-5","journal-title":"Lancet Neurol"},{"key":"3980_CR39","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14:9\u201321. https:\/\/doi.org\/10.1038\/nrneurol.2017.148","journal-title":"Nat Rev Neurol"},{"key":"3980_CR40","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3233\/JND-200560","volume":"8","author":"Y Aoki","year":"2021","unstructured":"Aoki Y, Wood MJA (2021) Emerging oligonucleotide therapeutics for rare neuromuscular diseases. J Neuromuscul Dis 8:869\u2013884. https:\/\/doi.org\/10.3233\/JND-200560","journal-title":"J Neuromuscul Dis"},{"key":"3980_CR41","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.toxrep.2015.05.008","volume":"2","author":"A Zhang","year":"2015","unstructured":"Zhang A, Uaesoontrachoon K, Shaughnessy C et al (2015) The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the Mdx mouse. Toxicol Rep 2:838\u2013849. https:\/\/doi.org\/10.1016\/j.toxrep.2015.05.008","journal-title":"Toxicol Rep"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03980-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03980-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03980-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:04:22Z","timestamp":1771859062000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03980-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3980"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03980-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}